Prosetta takes $5M from angels for anti-viral drugs
San Francisco drug developer Prosetta announced that it brought in $5 million in second-round funding to begin clinical trials on its lead compounds. All of the contributors were individuals, reports VentureWire.
So far, the company has resisted raising venture capital, relying solely on angel investors… Continue Reading
Nancy Pelosi’s biotech earmarks
(UPDATED: See below.)
House Speaker Nancy Pelosi apparently has a warm place in her heart for two San Francisco life-science companies. Buried inside a story on how the Democrat-led Congress seems almost as enthusiastic as its scandal-ridden Republican predecessor about “earmarks” that direct federal money to projects… Continue Reading
Prosetta, antiviral-drug developer, raises $2M
Prosetta, a San Francisco developer of new antiviral therapies, raised $2 million in early financing, VentureWire reports (subscription required). The company termed the funding a “series AAA” round that has the same terms as its earlier $1 million “series A” and $5 million “series AA”… Continue Reading